Sweden · Delayed Price · Currency is SEK Neola Medical AB Earnings Call Transcripts
Fiscal Year 2025
-
Entered clinical phase in 2025, secured SEK 20M in financing, and expanded IP portfolio with seven new patents. Clinical pilot in Sweden nears completion, with U.S. and European market launches targeted next. Cash reserves at SEK 60M; cost efficiency remains a focus.
-
Key milestones achieved in clinical and regulatory progress, including Swedish pilot study and U.S. study preparations. Financial position strengthened by SEK 20 million share issue and new patents granted in Europe and China. Strong market focus on U.S. and ongoing IP expansion.
Fiscal Year 2024
-
2024 saw a strategic shift to clinical validation, with key regulatory and technical milestones achieved. The company is preparing for a Swedish pilot study in H1 2025, followed by a pivotal U.S. study, while maintaining cost control and strong shareholder support.
-
Advanced to clinical validation phase, secured key patents, and maintained strong cost control while preparing for pivotal U.S. clinical studies. Revenue growth is expected from disposables, with a solid cash position supporting ongoing operations.
-
Key milestones achieved in Q2 2024 include clinical validation progress, U.S. subsidiary setup, and strengthened financials. Pivotal U.S. clinical study is planned for H1 2025, with market launch targeted for late 2025 or early 2026.